Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
Earnings for Ampio Pharmaceuticals, Inc. (AMPE)
Earnings in 2023 (TTM): $-8,632,000
According to Ampio Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-8,632,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Ampio Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-8,632,000 | $-8,632,000 |
| 2022 | $-16,337,000 | $-8,467,000 |
| 2021 | $-17,075,000 | $-12,485,000 |
| 2020 | $-15,894,000 | $-16,498,000 |
| 2019 | $-13,630,000 | $-8,684,000 |
| 2018 | $33.99 M | $33.99 M |
| 2017 | $-51,891,721 | $-51,891,945 |
| 2016 | $-19,163,562 | $-19,163,629 |
| 2015 | $-33,714,190 | $-32,010,242 |
| 2014 | $-39,048,938 | $-38,125,415 |
| 2013 | $-24,528,424 | $-24,008,558 |
| 2012 | $-11,593,113 | $-11,593,045 |
| 2011 | $-18,276,734 | $-18,359,234 |
| 2010 | $-8,053,395 | $-8,053,395 |
| 2009 | $-26,051 | $-26,051 |
| 2008 | $-31,881 | $-31,881 |
| 2007 | $-31,195 | $-31,995 |
| 2006 | $ | $-1,004 |